

**SIMPLE LETTER AGREEMENT**

This Simple Letter Agreement (“**Agreement**”) is made as of December 13<sup>th</sup>, 2022 (the “**Effective Date**”) by and between the **Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic** (Ústav organické chemie a biochemie AV ČR, v.v.i.), having seat at Flemingovo nám. 2, Praha 6, Czech Republic (“**IOCB**”), and **SHINE Technologies, LLC** registered in the state of Delaware, USA, and a place of business located at 3400 Innovation Court, Janesville, Wisconsin, 53546 USA, (“**SHINE**”).

**RECITALS**

**WHEREAS**, IOCB has developed a [REDACTED] which has properties for use in the field of producing medical isotopes (the “**IOCB Technology**”);

**WHEREAS**, SHINE has developed a [REDACTED]  
[REDACTED]  
[REDACTED]; and

**WHEREAS**, the Parties entered into the License Agreement having an Effective Date of April 29, 2019 (as amended, the “**License Agreement**”), whereby SHINE obtained the exclusive worldwide rights from IOCB to use the IOCB Technology to make, have made, use, sell, offer for sale, and import [REDACTED] and

**WHEREAS**, IOCB [REDACTED]  
[REDACTED]

**WHEREAS**, SHINE [REDACTED]  
[REDACTED]

**WHEREAS**, IOCB [REDACTED]  
[REDACTED]

**WHEREAS**, the Parties desire to clarify in a legally binding manner their respective rights and obligations in relation to any existing or future patents and patent applications.

**NOW, THEREFORE**, in consideration of the mutual covenants set forth herein and other good and valuable considerations, the receipt of which is hereby acknowledged, the parties hereto mutually agree as follows:

**1. AGREEMENT.**

**1.1** [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

**1.2 Removal of References.** In the spirit of collaboration and maintaining the relationship between the Parties, SHINE agrees to amend any and all pending applications for any patents. [REDACTED]

[REDACTED]

**1.3 Future Covenants.** In addition, SHINE covenants that it will not, in the future, amend any and all pending applications for any patents, [REDACTED]

[REDACTED]. SHINE will not, in the future, file any other patent applications claiming IOCB Technology without prior discussion and consent of IOCB.

**2. FINAL CLAUSES.**

- 2.1** This Agreement [REDACTED] [REDACTED] constitute a legally binding undertaking of the parties.
- 2.2** This Agreement shall remain in full effect regardless of the Term and termination or expiration of the License Agreement.
- 2.3** This Agreement may be executed in two (2) counterparts, each being an original and both will constitute together the same document.

**[SIGNATURE PAGE FOLLOWS]**

IN WITNESS WHEREOF, the parties hereby have executed this Addendum in duplicate originals, the day and year herein written, effective as of the signing by the party last to sign.

**SHINE Technologies, LLC**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: December 13<sup>th</sup>, 2022

**For the Institute of Organic Chemistry and  
Biochemistry of the Academy of Sciences of the  
Czech Republic (Ústav organické chemie a  
biochemie AV ČR, v.v.i):**

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: December 16<sup>th</sup>, 2022